Influence of CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Expression on the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma
Zhanzhan Li,Yajie Zhao
DOI: https://doi.org/10.2147/CMAR.S314925
2021-06-18
Cancer Management and Research
Abstract:Zhanzhan Li, 1 Yajie Zhao 2 1 Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410008, People's Republic of China; 2 Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410008, People's Republic of China Correspondence: Yajie Zhao Department of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Changsha, Hunan Province, 410008, People's Republic of China Tel +86-731-89753769 Email Background: The aim of this study was to investigate the influence of CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) expression on the survival of nasopharyngeal carcinoma (NPC) patients. Methods: A total of 140 non-metastatic NPC patients were retrospectively analyzed. The expression of CDKAL1 was detected by immunohistochemistry. Results: The CDKAL1-negative group exhibited better overall survival (OS) according to Kaplan–Meier curve analysis ( p = 0.006), with 5-year OS rates for the CDKAL1-negative and -positive groups of 89.7% and 70.2%, respectively. The CDKAL1-negative group also exhibited a tendency toward a better progression-free survival (PFS) rate. Multivariate analysis showed that CDKAL1 expression was independently associated with both OS ( p = 0.002) and PFS ( p = 0.043). Conclusion: CDKAL1 expression is an independent negative predictor of patient survival in non-metastatic NPC. Keywords: nasopharyngeal carcinoma, CDKAL1, overall survival, progression-free survival With the application of modern treatment modalities, the prognosis of nasopharyngeal carcinoma (NPC) has significantly improved. 1 , 2 For non-metastatic NPC, the 5-year overall survival (OS) has been reported to be between 62% and 90%. 3–6 The tumor‐node‐metastasis (TNM) staging system is the most widely used system for predicting the survival of NPC patients; however, due to the intrinsic heterogeneity of tumor cells, and because intratumor microenvironments are not considered in the TNM staging system, personalized biomarkers for the pathogenesis or progression of NPC are needed to predict patient survival more accurately. CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) is a protein-coding gene involved in post-transcriptional RNA modification. 7 Genome-wide association studies have shown that CDKAL1 is associated with susceptibility to type 2 diabetes. 8 , 9 Other studies have indicated that CDKAL1 may play a role in the carcinogenesis and prognosis of several types of cancer, including both breast and endometrial cancers; 10 , 11 however, the role of CDKAL1 in NPC has not yet been investigated. Therefore, we sought to examine the influence of CDKAL1 expression on the survival of patients with non-metastatic NPC. A total of 140 NPC patients were selected according to the following criteria: (1) pathologically confirmed non-metastatic NPC patients [according to the American Joint Committee on Cancer (AJCC), staging system (7th edition)]; (2) received definitive radiotherapy with or without other treatments at Xiangya Hospital, Central South University between August 2008 and January 2012; and (3) availability of pathology specimens for immunohistochemistry. The study was approved by the Research and Ethics Committee of Xiangya Hospital. Written informed consent was obtained from all subjects. This study was conducted in accordance with the Declaration of Helsinki. All patients were treated with intensity-modulated radiation therapy (IMRT). The target volumes included the gross tumor volume of the nasopharynx (GTVnx), the gross tumor volume of lymph nodes (GTVnd), clinical target volume 1 (CTV1), and clinical target volume 2 (CTV2). CTV1 and CTV2 were defined as the high- and low-risk volume, respectively. Areas of 3–5 mm around the GTVnx, GTVnd, CTV1, and CTV2 were included in the planning target volumes (PGTVnx, PGTVnd, PTV1, and PTV2, respectively). The doses to the PGTVnx, PGTVnd, PTV1, and PTV2 were 66–73.92 Gy (33 fractions), 59.6 to 72– Gy (33 fractions), 50.4–66 Gy (33 fractions), and 50.4–61.05 Gy (33 fractions), respectively. The dose limits for the organs at risk (OARs), and the PTVs, were based on protocol 0225 of the Radiation Therapy Oncology Group (RTOG). 12 Neoadjuvant chemotherapy was administered when the waiting time for radiotherapy was too long or the tumor was too large. Concurrent chemotherapy was administered in patients with cancer st -Abstract Truncated-
oncology